Special Issue "Gut Microbial Dysbiosis in Disease Pathogenesis"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Microbiology in Human Health and Disease".

Deadline for manuscript submissions: 31 January 2024 | Viewed by 2079

Special Issue Editors

School of Medicine, University of Kansas Medical Center, Kansas City, KS, USA
Interests: microbiome; chronic inflammation; nutrition; cancer
Special Issues, Collections and Topics in MDPI journals
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
Interests: gut microbiota and host immune; microbiome; gut-brain axis; gut inflammation; probiotics and nutrition

Special Issue Information

Dear Colleagues,

The gut microbiota is considered an invisible organ of the human system due to its multiple functional roles. There is no stable microbial composition, and the normal microbial composition varies between different age groups. This is an adaptive and dynamic system that reflects the health status and can be a potential biomarker in the future. The microbiota plays important role in training the immune system and various metabolic pathways. The overuse of antibiotics, poor diet, and lifestyle are some of the factors that affect the healthy microbial composition leading to microbial dysbiosis.

The role of microbial dysbiosis in causing diseases is clear from the increase in allergic and autoimmune diseases observed in developing countries as seen in developed countries. This is attributed to changes in diet and lifestyle that are considered to affect the microbiota.

With affordable next-generation sequencing, microbiome studies are conducted at small and large scales to explore various human diseases. Many such studies observed microbial dysbiosis in various disease conditions. These studies mostly profiled dysbiosis. Microbiome studies in the future are required to establish the mechanistic role of microbial dysbiosis in various disease pathogenesis.

This special issue invites original research and review articles that expand our knowledge on the role of dysbiosis in disease pathogenesis. The studies conducted in animal models and human subjects will be accepted for submission.

Dr. Pugazhendhi Srinivasan
Dr. Nanda Kumar Navalpur Shanmugam
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microbiome
  • dysbiosis
  • pathogenesis
  • metabolomics
  • probiotics
  • fecal microbial transplant

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

34 pages, 3597 KiB  
Article
Prophylactic Effect of Bovine Colostrum on Intestinal Microbiota and Behavior in Wild-Type and Zonulin Transgenic Mice
Biomedicines 2023, 11(1), 91; https://doi.org/10.3390/biomedicines11010091 - 29 Dec 2022
Cited by 4 | Viewed by 1820
Abstract
The microbiota–gut–brain axis (MGBA) involves bidirectional communication between intestinal microbiota and the gastrointestinal (GI) tract, central nervous system (CNS), neuroendocrine/neuroimmune systems, hypothalamic–pituitary–adrenal (HPA) axis, and enteric nervous system (ENS). The intestinal microbiota can influence host physiology and pathology. Dysbiosis involves the loss of [...] Read more.
The microbiota–gut–brain axis (MGBA) involves bidirectional communication between intestinal microbiota and the gastrointestinal (GI) tract, central nervous system (CNS), neuroendocrine/neuroimmune systems, hypothalamic–pituitary–adrenal (HPA) axis, and enteric nervous system (ENS). The intestinal microbiota can influence host physiology and pathology. Dysbiosis involves the loss of beneficial microbial input or signal, diversity, and expansion of pathobionts, which can lead to loss of barrier function and increased intestinal permeability (IP). Colostrum, the first milk from mammals after birth, is a natural source of nutrients and is rich in oligosaccharides, immunoglobulins, growth factors, and anti-microbial components. The aim of this study was to investigate if bovine colostrum (BC) administration might modulate intestinal microbiota and, in turn, behavior in two mouse models, wild-type (WT) and Zonulin transgenic (Ztm)—the latter of which is characterized by dysbiotic microbiota, increased intestinal permeability, and mild hyperactivity—and to compare with control mice. Bioinformatics analysis of the microbiome showed that consumption of BC was associated with increased taxonomy abundance (p = 0.001) and diversity (p = 0.004) of potentially beneficial species in WT mice and shifted dysbiotic microbial community towards eubiosis in Ztm mice (p = 0.001). BC induced an anxiolytic effect in WT female mice compared with WT female control mice (p = 0.0003), and it reduced anxiogenic behavior in Ztm female mice compared with WT female control mice (p = 0.001), as well as in Ztm male mice compared with WT BC male mice (p = 0.03). As evidenced in MGBA interactions, BC supplementation may well be applied for prophylactic approaches in the future. Further research is needed to explore human interdependencies between intestinal microbiota, including eubiosis and pathobionts, and neuroinflammation, and the potential value of BC for human use. The MGH Institutional Animal Care and Use Committee authorized the animal study (2013N000013). Full article
(This article belongs to the Special Issue Gut Microbial Dysbiosis in Disease Pathogenesis)
Show Figures

Figure 1

Back to TopTop